@Agency and @Manufacturer

We invite you to participate in our annual client survey, where your feedback will directly inform our future improvements.

About the survey:
• This quick, 10-minute survey is for everyone who works with PAAB, whether directly or indirectly.
• Your responses are entirely anonymous, all insights will be presented in aggregate via our research partner, CreateHealth.io.

To thank you for your input, you’ll receive a digital $10 CAD gift card (Visa and select store cards) upon completion.

Please note, to receive the $10 honoraria, you must provide your work email at the end of the survey, and it must be associated with your forum registration, eFiles records, or PAAB email list.

Share you views here today

Thank you in advance for your feedback!
PAAB

Hi @costeap,

We are nearing completion of the messenger programming, however due to issues we uncovered during previous testing we are not in a position to provide a firm launch date just yet. Assuming testing of the most recent updates go smoothly, we are aiming for launch the third week of May. We will be following up soon with a firm launch date as well as more information on how to use Messenger.

@jennifer-carroll this is excellent news. I read the guidance document today.

@jennifer-carroll Thank you so much! This should help us learn 🙂

Hey @palanski

Great question. PAAB’s strategic plan for 2023-2025 includes a focus on increasing the extent to which HCPs value health product advertising and industry-generated patient information. This is the primary motivation for the shift outlined in the disease burden document. This shift is one element of a multi-pronged approach towards that aim. The standards outlined in the document were generated in consideration of our global benchmarking and stakeholder consultation activities.

While health product manufacturers’ have expressed a long-standing desire to provide more detailed presentations of disease states, it took some time to establish a set of standards that effectively aligned that desire with the interests of patients and HCPs. The objective of PAAB is to ensure that disease information (including burden of disease) does not suggest use and efficacy for outcomes which the brand has not been demonstrated to address. This objective remains however PAAB has looked to explore ways that we can meet this objective while allowing more latitude on disease presentations.

In short, the document seeks to outline principles that will mitigate the risk that the disease burdens be interpreted as outcomes that the drug can improve. The document also reiterates the requirement that the disease information and descriptions of disease burden must pertain to the promoted product’s indication.

Our hope is that manufactures will view the guidance document as a collaborative means to providing greater flexibility in relation to disease information presentations in HCP advertising, disease information presentations in patient information, and disease burdens conveyed in creative imagery.